Search - tctmd.com

Displaying 201 - 220 of 707

Sort: Relevancy | Date

Presentation TCT 2019

Reconciling Adjudicated Data Within a Global Trial

Presenter: Marco Valgimigli

September 26, 2019

Presentation TCT 2019

Transitioning to Monotherapy in Patients After PCI

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Deep Dive

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Daily News

TAVR Bleeds Stand Apart From PCI-Related Events

Caitlin E. Cox

August 06, 2019

News Conference News EuroPCR 2019

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

L.A. McKeown

May 31, 2019

News Conference News EuroPCR 2019

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Michael O'Riordan

May 21, 2019

Taking Ticagrelor? Frank, Proactive Patient Conversations are Needed to Help With Adherence

News Daily News

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

Yael L. Maxwell

May 17, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Conference News ACC 2019

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Shelley Wood

March 19, 2019

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Advertisement

Reconciling Adjudicated Data Within a Global Trial

Transitioning to Monotherapy in Patients After PCI

TWILIGHT: A Deep Dive

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

TAVR Bleeds Stand Apart From PCI-Related Events

ROBOT-ACS: Real-World Data Reiterate Ticagrelor’s Safety

Long-term Ticagrelor Monotherapy May Have an Edge in Complex PCI Patients: GLOBAL LEADERS

Taking Ticagrelor? Frank, Proactive Conversations are Needed to Help With Adherence

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

No TREAT for Ticagrelor at 12 Months: Fibrinolysis Patients After STEMI Do Just as Well on Clopidogrel

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content